

<i>Policy #:</i>	2.0	<i>Origination Date:</i>	2005
<i>Subject:</i>	CE Program and Mission Statement	<i>Date of Last Revision:</i>	March 2016

Program Structure and History

The Food and Drug Administration’s (FDA), continuing education (CE) program is in the Center for Drug Evaluation and Research’s (CDER) Office of Executive Programs (OEP), Division of Learning and Organizational Development (DLOD), CE Consultation and Accreditation Team (CECAT). The CE program has served a multidisciplinary group of physicians, pharmacologists, chemists, toxicologists, microbiologists, statisticians, pharmacists and nurses since its inception. It is committed to providing interprofessional education to FDA employees and stakeholders to support and further their scientific expertise and professional development as it relates to regulatory development, research, review, and policy.

CECAT consists of the Associate Director for Accreditation (CE Program Administrator), a CE Team Leader and CE Consultants. The CECAT members work collaboratively with individuals serving in different roles throughout the FDA to ensure the CE program successfully meets the FDA/CDER CE mission. CE program roles and duties are outlined below:

- CE Program Administrator: a designated individual from DLOD who oversees the CE Program and is the final signatory/approving official for all CE activities
- CE Activity Coordinator: a designated individual from DLOD or other FDA Office/Center who is responsible for the coordination of the educational activity
- CE Consultant: a designated CECAT member with CE expertise who provides consultation to the CE Developer throughout the CE application process to ensure activities meet FDA/CDER’s CE mission and the accreditation standards
- Activity Director: a designated FDA individual who shares their expertise to provide guidance to the planning committee and CE Developer in all developmental aspects such as the need and content for an activity

FDA CDER CE Mission Statement

Purpose

The FDA is committed to providing Interprofessional Continuing Education (IPCE) to FDA’s multi-disciplinary healthcare professionals and its scientific community to support and sustain their scientific expertise and professional competence as it relates to product research and development, regulatory review and policy issues. The IPCE program aims to create meaningful, collaborative, interactive learning experiences where FDA multidisciplinary health professionals and scientists can learn with, from, and about each other’s views and perspectives on their different regulatory practices.

Target Audience

The FDA CE activities are made available to physicians, pharmacists, nurses, clinical, and non-clinical scientists. The development of these CE activities is based primarily on providing learning opportunities in essential and advancing areas of the medical sciences, and path-breaking technologies. These programs are in accordance with the stated mission of the FDA to protect the public health by regulating tobacco products and assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.

Types of Activities Provided

FDA offers a wide range of CE activities which include:

- Scientific Rounds and Scientific Seminars;
- Courses, Workshops and Journal Clubs;
- Internet-based enduring materials which includes Outreach Initiatives for the Public Health;
- Special Topics

The educational design and instructional methods for CE activities are selected based on the identified needs, professional practice gaps, learning objectives, learning activities, and the expected results of the activities.

Content Areas

The content of FDA CE activities centers around the latest integrated science and technology related to the FDA's regulatory mission and every stage of the product life cycle from pre-market testing and development through post-market surveillance and risk management. Activity topics address the science-based standards and safety measures that are related to tobacco products, human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation.

Expected Results

The FDA is committed to assessing the impact and effectiveness of its CE program to ensure that the program continues to contribute to interprofessional practice improvement of the healthcare team, as well as continuing to be based on valid content and independent of commercial interests. Our organization employs a post-activity evaluation tool that allows learners to rate the projected impact of the FDA CE activities on their competence, performance, and/or patient/public health outcomes. Feedback from the post-activity evaluation is used in a systematic fashion for the purpose of ongoing improvements to the overall CE program and to assess whether the FDA's stated CE mission is achieved. The expected result of the FDA CE program is to change competence, performance, and/or patient/public health outcomes of the healthcare team that are essential to accomplishing FDA's regulatory mission.